Teva Pharmaceutical Industries (TEVA) Upgraded to Buy at Goldman Sachs Group

Goldman Sachs Group upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a neutral rating to a buy rating in a report published on Friday, MarketBeat reports. The brokerage currently has $20.00 price objective on the stock.

A number of other research firms also recently weighed in on TEVA. BidaskClub raised Teva Pharmaceutical Industries from a strong sell rating to a sell rating in a research note on Wednesday, September 13th. Gabelli reaffirmed a buy rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, September 13th. UBS reaffirmed a neutral rating and set a $19.00 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Maxim Group reaffirmed a hold rating and set a $15.50 price target on shares of Teva Pharmaceutical Industries in a research note on Thursday, September 14th. Finally, BTIG Research reissued a buy rating and set a $24.00 price objective on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Teva Pharmaceutical Industries has a consensus rating of Hold and an average price target of $20.68.

Teva Pharmaceutical Industries (NYSE TEVA) opened at $18.52 on Friday. Teva Pharmaceutical Industries has a 52 week low of $10.85 and a 52 week high of $38.31. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The firm has a market capitalization of $18,907.76, a P/E ratio of 4.30 and a beta of 0.55.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th were issued a $0.085 dividend. This represents a $0.34 annualized dividend and a dividend yield of 1.84%. The ex-dividend date of this dividend was Monday, November 27th. Teva Pharmaceutical Industries’s dividend payout ratio is presently -12.10%.

Several hedge funds have recently added to or reduced their stakes in the company. Security National Bank of Sioux City Iowa IA grew its holdings in shares of Teva Pharmaceutical Industries by 0.4% in the second quarter. Security National Bank of Sioux City Iowa IA now owns 21,788 shares of the company’s stock valued at $724,000 after acquiring an additional 87 shares in the last quarter. Bronfman E.L. Rothschild L.P. grew its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after acquiring an additional 94 shares in the last quarter. Sheaff Brock Investment Advisors LLC grew its holdings in shares of Teva Pharmaceutical Industries by 3.6% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 8,389 shares of the company’s stock valued at $279,000 after acquiring an additional 294 shares in the last quarter. Bank of Nova Scotia grew its holdings in shares of Teva Pharmaceutical Industries by 8.3% in the second quarter. Bank of Nova Scotia now owns 6,903 shares of the company’s stock valued at $229,000 after acquiring an additional 528 shares in the last quarter. Finally, First National Trust Co. grew its holdings in shares of Teva Pharmaceutical Industries by 6.7% in the second quarter. First National Trust Co. now owns 8,878 shares of the company’s stock valued at $295,000 after acquiring an additional 555 shares in the last quarter. 52.05% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This article was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally stolen and reposted in violation of US and international copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/12/19/teva-pharmaceutical-industries-teva-upgraded-to-buy-at-goldman-sachs-group.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply